Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease
Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer’s ...
Cerence AI Adds Former Ford Executive Marion Harris to its Board of Directors
“On behalf of the Cerence AI leadership team, we are delighted to welcome Marion to our Board of Directors,” said Brian Krzanich, CEO, Cerence AI. “Marion’s extensive experience will bring invaluable ...